Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

W.R. Grace expands manufacturing plant in Michigan

By Sean Whooley | March 19, 2024

WR Grace logoW.R. Grace announced that it opened an expanded fine chemical contract development and manufacturing plant in Michigan.

The Columbia, Maryland-based specialty chemicals company opened the facility in South Haven, Michigan. Following a 21-month project, more than 200 employees joined executives and community leaders for a ribbon-cutting ceremony this week.

Grace’s facility has 25% more capacity, with more room for a 4,000-gallon Hastelloy centrifuge and three 4,000-gallon, multi-use chemical reactors. This strengthens Grace’s ability to serve growing demand for active pharmaceutical ingredients (APIs).

The company’s South Haven facility produces APIs, regulatory starting materials (RSMs) and drug intermediates in quantities from kilos to tons. It lands in compliance with the FDA’s current Good Manufacturing Practice (cGMP) regulations. The site integrates with Grace’s Tyrone, Pennsylvania facility, the company said. It offers customer flexibility in meeting pharmaceutical and nutraceutical production needs with a U.S.-based supply chain.

“The newly expanded South Haven facility cements our position as a leading North American contract development and manufacturing organization (CDMO) and a leading employer in the community,” said Ed Sparks, Chief Executive Officer, Grace. “Equally important, the expansion solidifies our commitment to helping our fine chemical customers bring life-saving and life-changing drug therapies to people everywhere.”

“The additional capacity and cutting-edge equipment in South Haven bolster our ability to grow with our current and future customers through every stage of fine chemical manufacturing – from research and development, to clinical trials, scale-up services and commercial production of custom molecules and compounds,” said Brenda Kelly, President, Materials Technologies, Grace.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE